| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/18/2007 | CA2615077A1 Use of 3,1ib-cis-dihydrotetrabenazine for the treatment of symptoms of huntington's disease |
| 01/18/2007 | CA2615055A1 Ppar [alpha/gamma] agonists and processes of preparing |
| 01/18/2007 | CA2615053A1 Pharmaceutical formulations of endo-n-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-1-methyl-1h-indazole-3-carboxamide hydrochloride |
| 01/18/2007 | CA2615028A1 Cross-.beta. structure binding compounds |
| 01/18/2007 | CA2615025A1 A method for detecting peptides comprising a cross-.beta. structure |
| 01/18/2007 | CA2615007A1 Benzimidazole derivatives as 5-ht6,5-ht24 |
| 01/18/2007 | CA2614930A1 Glutamate aggrecanase inhibitors |
| 01/18/2007 | CA2614834A1 Combination of a dpp-iv inhibitor and a cannabinoid cb1 receptor antagonist |
| 01/18/2007 | CA2614833A1 Pharmaceutical composition comprising 2, 3-disubstituted tropanes for the treatment of disorders of sexual desire |
| 01/18/2007 | CA2614726A1 New pyridine analogues |
| 01/18/2007 | CA2614698A1 Use of mglur5 (esp. afq056) in gi (esp. gerd) |
| 01/18/2007 | CA2614696A1 Use of 4-(3,4-dichloro-phenyl)-1,2,3,4-tetrahydro-naphtalen-1-ylamine for treating cancer |
| 01/18/2007 | CA2614691A1 Piperidine derivatives useful in the diagnostic and therapeutic treatment of diseases depending on renin activity |
| 01/18/2007 | CA2614688A1 N-dihydroxyalkyl-substituted 2-oxo-imidazole derivatives |
| 01/18/2007 | CA2614680A1 Il-32 modulators |
| 01/18/2007 | CA2614627A1 Methods and compositions for treating ophthalmic conditions via serum retinol, serum retinol binding protein (rbp), and/or serum retinol-rbp modulation |
| 01/18/2007 | CA2614622A1 New combination of anti-madcam antibody and antifibrotic caspase inhibitor to treat liver fibrosis |
| 01/18/2007 | CA2614597A1 Novel 2,4-dianilinopyrimidine derivatives, the preparation thereof, their use as medicaments, pharmaceutical compositions and, in particular, as ikk inhibitors |
| 01/18/2007 | CA2614582A1 New derivatives of heptaazaphenalene, methods for obtaining them, and their use as protecting agents against uv radiation |
| 01/18/2007 | CA2614545A1 Choline salt crystal of azulene compound |
| 01/18/2007 | CA2614544A1 Heterocycle-substituted benzimidazole derivative |
| 01/18/2007 | CA2614531A1 Nucleic acid agents for downregulating h19, and methods of using same |
| 01/18/2007 | CA2614528A1 Synergistic combination for the treatment of pain (cannabioid receptor agonist and opiod receptor agonist) |
| 01/18/2007 | CA2614518A1 Dicycloalkyl urea glucokinase activators |
| 01/18/2007 | CA2614503A1 Metered-dose and safety and compliance packaging for systemic anticancer therapy |
| 01/18/2007 | CA2614473A1 Polyunsaturated fatty acids for treatment of dementia and pre-dementia-related conditions |
| 01/18/2007 | CA2614420A1 Fentanyl formulation containing an essential oil |
| 01/18/2007 | CA2614385A1 Pyridazine compounds as glycogen synthase kinase 3 inhibitors |
| 01/18/2007 | CA2614324A1 Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer |
| 01/18/2007 | CA2614320A1 Anti-ctla-4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment |
| 01/18/2007 | CA2614276A1 Antiviral compounds |
| 01/18/2007 | CA2614191A1 Antisense antibacterial method and compound |
| 01/18/2007 | CA2614185A1 Methods of dosing propofol prodrugs for inducing mild to moderate levels of sedation |
| 01/18/2007 | CA2614147A1 Benzoimidazole compound capable of inhibiting prostaglandin d synthetase |
| 01/18/2007 | CA2614121A1 Thiazole derivatives for the treatment of dyskinesias caused by a chemical treatment |
| 01/18/2007 | CA2614048A1 Improved crystalline form of the compound a-348441 |
| 01/18/2007 | CA2614000A1 Novel 1h-indole-pyridinecarboxamide and 1h-indole- piperidinecarboxamine derivatives, process for their preparation and pharmaceutical compositions containing them |
| 01/18/2007 | CA2613976A1 New pharmaceutical compositions containing hyaluronic acid and collagenase for the topical treatment of wounds, burns and ulcers |
| 01/18/2007 | CA2613458A1 Compounds with activity at retinoic acid receptors |
| 01/18/2007 | CA2613141A1 Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders |
| 01/18/2007 | CA2612841A1 Inhibitors of checkpoint kinases |
| 01/18/2007 | CA2612765A1 Antidiabetic oxazolidinediones and thiazolidinediones |
| 01/18/2007 | CA2612752A1 Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents |
| 01/18/2007 | CA2612506A1 Methods of treatment using hydroquinone ansamycins |
| 01/18/2007 | CA2612442A1 Heterotetracyclic compounds as tpo mimetics |
| 01/18/2007 | CA2612260A1 Apoptosis promoters |
| 01/18/2007 | CA2612211A1 Modified poly(propylene-imine) dendrimers and their use as transfection agents for anionic bioactive factors |
| 01/18/2007 | CA2611607A1 Indolylmaleimide derivatives |
| 01/18/2007 | CA2610817A1 Cysteine protease inhibitors |
| 01/18/2007 | CA2610481A1 3-ester prodrugs of estradiol |
| 01/18/2007 | CA2610210A1 1-[2' ,3'-dideoxy-3'c- (hydroxymethyl)- beta-d-erythro-pentofuranosyl cytosine derivatives as hiv inhibitors |
| 01/18/2007 | CA2609597A1 Method for evaluating the effects of smoke on bronchioles |
| 01/18/2007 | CA2603115A1 3-spirocyclopropyl2-oxindole kinase inhibitors |
| 01/18/2007 | CA2602453A1 Kinase inhibitors |
| 01/18/2007 | CA2602389A1 Kinase inhibitors |
| 01/18/2007 | CA2599531A1 Metformin methods and formulations for treating chronic constipation |
| 01/18/2007 | CA2578336A1 Wortmannin analogs and methods of using same in combination with chemotherapeutic agents |
| 01/17/2007 | EP1743945A1 Screening method |
| 01/17/2007 | EP1743897A1 Biologically active compounds obtainable from Sorangium cellulosum |
| 01/17/2007 | EP1743895A1 Muscle relaxation accelerator and therapeutic agent for muscular tissue diseases such as muscle relaxation failure |
| 01/17/2007 | EP1743894A1 Heterocyclyl-substituted pyrazoline compounds, their preparation and use as medicaments |
| 01/17/2007 | EP1743893A1 Stable lansoprazole containing more than 500 ppm, up to about 3,000 ppm water and more than 200 ppm, up to about 5,000 ppm alcohol |
| 01/17/2007 | EP1743892A1 Substituted pyrazoline compounds, their preparation and use as medicaments |
| 01/17/2007 | EP1743891A1 Heterocyclic compounds and methods for modulating CXCR3 function |
| 01/17/2007 | EP1743890A1 4,5-Dihydro-1H-pyrazole derivatives, their preparation and use as medicaments |
| 01/17/2007 | EP1743888A1 Carbonyl substituted pyrazoline compounds, their preparation and use as CB1 receptor modulators |
| 01/17/2007 | EP1743887A1 Thiocarbonyl-substituted pyrazoline compounds, their preparation and use as CB1 modulators |
| 01/17/2007 | EP1743886A1 Method of inhibiting neurotrophin-receptor binding |
| 01/17/2007 | EP1743885A2 TNF-Alpha Produktion Hemmer zur Behandlung von Autoimmunerkrankungen |
| 01/17/2007 | EP1743884A1 Progrugs to d-prolines |
| 01/17/2007 | EP1743883A1 Use of biphenyl-derived thiamides as calpain inhibitors |
| 01/17/2007 | EP1743881A1 Phenyl-benzyl-ketones |
| 01/17/2007 | EP1743676A1 Heterocyclic boronic acid derivatives, dipeptidyl peptidase IV inhibitors |
| 01/17/2007 | EP1743657A2 Stabilisation of macrolides |
| 01/17/2007 | EP1743656A2 Pharmaceutical combination for the treatment of benign prostatic hyperplasia or for the long-term prevention of acute urinary retention |
| 01/17/2007 | EP1743655A1 Combinations comprising dipeptidylpeptidase-IV inhibitors and antidiabetic agents |
| 01/17/2007 | EP1743654A1 Use of inhibitors of histone deacetylases in combination with NSAID for the therapy of cancer and/or inflammatory diseases |
| 01/17/2007 | EP1743646A2 Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels |
| 01/17/2007 | EP1743645A1 Adhesive patch |
| 01/17/2007 | EP1743644A1 Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia |
| 01/17/2007 | EP1743643A1 New formulations of substituted pyrazoline compounds |
| 01/17/2007 | EP1743642A1 Use of substituted pyrazoline compounds and their derivatives for the treatment of cannabinoid system-associated diseases |
| 01/17/2007 | EP1743641A1 Use of substituted pyrazoline compounds for the treatment of food disorders, including obesity or metabolic syndrome in patients with developed diabetes |
| 01/17/2007 | EP1743640A1 Use of substituted pyrazoline compounds for the preparation of paediatric medicaments |
| 01/17/2007 | EP1743639A1 Use of substituted pyrazoline compounds for the treatment of coagulation related diseases |
| 01/17/2007 | EP1743638A1 Pharmaceutical formulations of substituted pyrazoline compounds |
| 01/17/2007 | EP1743637A1 Use of substituted pyrazole compounds and combinations thereof for the treatment of the metabolic syndrome |
| 01/17/2007 | EP1743636A1 Combination of a substituted pyrazoline compound and a drug used in food-related disorders |
| 01/17/2007 | EP1743635A2 Gibberellins for the promotion of ulcer healing |
| 01/17/2007 | EP1743634A1 Alcohol metabolism accelerating composition, and food or drink containing the composition |
| 01/17/2007 | EP1743633A1 Sleep-improving composition |
| 01/17/2007 | EP1743632A1 Novel 4-dedimethy laminotetracycline derivatives |
| 01/17/2007 | EP1743631A2 Use of an amphetamine composition for regulating memory consolidation |
| 01/17/2007 | EP1743630A2 Pharmaceutical combination |
| 01/17/2007 | EP1743629A1 Process for preparing oral calcium compositions |
| 01/17/2007 | EP1743531A1 Aggregates of eyeballs of crustaceans, usage, foods coataining the same, and production processes |
| 01/17/2007 | EP1743170A2 Methods for detecting substances which bind to the amyloid precursor protein or beta amyloid fragments, and binding compounds |
| 01/17/2007 | EP1742971A2 N-acylated chitinous polymers and methods of use thereof |
| 01/17/2007 | EP1742960A2 Crystalline and amorphous forms of smilagenin |
| 01/17/2007 | EP1742952A1 (poly) aminoacetamide derivatives of epipodophyllotoxin, their process of preparation and their applications in therapeutics as anticancer agents |